JW Pharmaceutical开展胆固醇日内部他汀科普活动，未形成可交易业绩催化

JW Pharmaceutical (001060) has begun promoting accurate information about dyslipidemia and statin treatment to mark Cholesterol Day. The company started with its own employees, having them review cardiovascular risk factors and LDL cholesterol treatment targets to underscore the need for patients to manage the condition consistently.
JW Pharmaceutical said on the 4th that it held the "Dangbu, Statin" in-house campaign for employees at its JW headquarters in Gwacheon, Gyeonggi Province, to mark Cholesterol Day.
"Dangbu, Statin" is a campaign designed to deliver information that dyslipidemia patients need during treatment in an accessible way, improving their understanding of disease management and statin therapy.
Employees used a checklist on the campaign website to review their cardiovascular risk factors and LDL cholesterol treatment targets. They also shared health information that patients should monitor while taking statins, including blood sugar, muscle and liver conditions.
Dyslipidemia is closely linked to the risk of cardiovascular disease and requires consistent management, but it is a chronic condition with no clear symptoms, making it difficult for patients to recognize the need for treatment.
"'Dangbu, Statin' is a campaign that helps patients understand their own condition and continue treatment through consultation with medical professionals," an official at JW Pharmaceutical said. "We will continue to provide disease management information that patients can easily understand and put into practice in their daily lives."
JW Pharmaceutical supplies dyslipidemia treatments through its "Livalo family" portfolio, which includes the pitavastatin drugs Livalo and Livalo Zet.